You are here

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bruxelles, , 1200 Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Neovascular AMD patients who are eligible for Macugen therapy based on the approved
label

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Active or suspected ocular or periocular infection. Known hypersensitivity to the
active substance or any of its excipients.

NCT00460408
Pfizer
Completed
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration
NCT01245387
All Genders
Macular Degeneration
NCT00460408
All Genders
18+
Years
Multiple Sites
Neovascular Age-related Macular Degeneration
NCT00549055
All Genders
0+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now